日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).

一项针对一线治疗后晚期食管胃癌患者的瑞戈非尼和紫杉醇 Ib/II 期研究 (REPEAT)

Stroes Charlotte I, Schokker Sandor, Khurshed Mohammed, van der Woude Stephanie O, Mathôt Ron Aa, Slingerland Marije, de Vos-Geelen Judith, Zucchetti Massimo, Matteo Cristina, van Dijk Erik, Ylstra Bauke, Thijssen Victor, Derks Sarah, Godefa Tesfay, Dijksterhuis Willemieke, Breimer Gerben E, van Delden Otto M, Verhoeven Rob Ha, Meijer Sybren L, Bijlsma Maarten F, van Laarhoven Hanneke Wm

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

一项II期研究表明,对于可切除的食管腺癌,采用六个周期的S-1和奥沙利铂辅助治疗不可行,ERCC1可作为SOX疗效的生物标志物。

Stroes, Charlotte I; Schokker, Sandor; Molenaar, Remco J; Mathôt, Ron A A; Bijlsma, Maarten F; van der Woude, Stephanie O; Belo Pereira, João P; Hooijer, Gerrit K J; Verhoeven, Rob H A; Cats, Annemieke; Grootscholten, Cecile; van Sandick, Johanna W; Creemers, Geert-Jan; Nieuwenhuijzen, Grard A P; Haj Mohammad, Nadia; Ruurda, Jelle P; Meijer, Sybren L; Hulshof, Maarten C C M; van Berge Henegouwen, Mark I; van Laarhoven, Hanneke W M

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study

曲妥珠单抗和帕妥珠单抗联合放化疗治疗可切除的人表皮生长因子受体2阳性食管腺癌的II期可行性和生物标志物研究:TRAP研究

Stroes, Charlotte I; Schokker, Sandor; Creemers, Aafke; Molenaar, Remco J; Hulshof, Maarten C C M; van der Woude, Stephanie O; Bennink, Roel J; Mathôt, Ron A A; Krishnadath, Kausilia K; Punt, Cornelis J A; Verhoeven, Rob H A; van Oijen, Martijn G H; Creemers, Geert-Jan; Nieuwenhuijzen, Grard A P; van der Sangen, Maurice J C; Beerepoot, Laurens V; Heisterkamp, Joos; Los, Maartje; Slingerland, Marije; Cats, Annemieke; Hospers, Geke A P; Bijlsma, Maarten F; van Berge Henegouwen, Mark I; Meijer, Sybren L; van Laarhoven, Hanneke W M

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy

晚期食管胃癌患者接受姑息化疗时,体成分、生存率和毒性之间的关联

Dijksterhuis, Willemieke P M; Pruijt, Maarten J; van der Woude, Stephanie O; Klaassen, Remy; Kurk, Sophie A; van Oijen, Martijn G H; van Laarhoven, Hanneke W M

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

在转移性食管胃腺癌的一线治疗中,将纳米白蛋白紫杉醇添加到卡培他滨和奥沙利铂(CapOx)中,进行 I 期剂量递增研究及扩展队列研究(ACTION 研究)

Schokker Sandor, van der Woude Stephanie O, van Kleef Jessy Joy, van Zoen Daan J, van Oijen Martijn G H, Mearadji Banafsche, Beenen Ludo F M, Stroes Charlotte I, Waasdorp Cynthia, Jibodh R Aarti, Creemers Aafke, Meijer Sybren L, Hooijer Gerrit K J, Punt Cornelis J A, Bijlsma Maarten F, van Laarhoven Hanneke W M

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients

CT放射组学预测食管胃癌患者肝转移灶治疗反应的可行性

Klaassen, Remy; Larue, Ruben T H M; Mearadji, Banafsche; van der Woude, Stephanie O; Stoker, Jaap; Lambin, Philippe; van Laarhoven, Hanneke W M

Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer

两例晚期食管胃癌患者在接受雷莫芦单抗输注期间出现急性高血压

van der Woude, Stephanie O; van Laarhoven, Hanneke W M